Announcement on Change of Sponsor Representative
Filed with SSE · · 2 pages · Chinese
Shanghai MicuRx Pharmaceutical Co., Ltd. on 6ix
Earlier from Shanghai MicuRx Pharmaceutical
- Notice on Convening the 1st Extraordinary General Meeting in 2025
- Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2024 Annual Report
- Announcement on Resolution of the 2024 Annual General Meeting
- Announcement on the Voluntary Disclosure of Acceptance of the New Drug Application for the Marketing Authorization of Contezolid Acefosamil Sodium for Injection
- Announcement on Convening the Q1 2025 Performance Briefing
Later from Shanghai MicuRx Pharmaceutical
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
- Announcement on Continued Use of Idle Raised Funds Used for Cash Management
- Announcement on Resignation and Appointment of Deputy General Manager
- Shareholder's Inquiry Transfer Plan
- Indicative Announcement on Pricing for Shareholder Inquiry Transfer
Follow Shanghai MicuRx Pharmaceutical into a list and get an email when it puts out news.
Follow Shanghai MicuRx Pharmaceutical